Introduction: Virus surveillance strategies and genetic characterization of human parvovirus B19 (B19V) are important tools for regional and global control of viral outbreak. In São Paulo, Brazil, we performed a study of B19V by monitoring the spread of this virus, which is an infectious agent and could be mistakenly reported as a rash and other types of infection. Method: Serum samples were subjected to enzyme immunoassay, real time polymerase chain reaction, and sequencing. Results: From the 462 patients with suspected cases of exanthematic infections, the results of the 164 serum samples were positive for B19V immunoglobulin M. Among these cases, there were 38 patients with erythema infections and B19--associated with other infections such as encephalitis, hydrops fetalis, chronic anemia, hematological malignancies. These samples were sequenced and identified as genotype 1. Conclusion: This study showed patients with infections caused by B19V and sequencing genotype 1. Continuous monitoring is necessary to detect all known genotypes, and the emergence of new genotypes of these viruses for case management in public health control activities.
introduction
Human parvovirus B19 (B19V) is a member of the Parvoviridae family. It is further classified into the subfamily Parvovirinae, genus Erythrovirus, and species Parvovirus B19. B19V causes erythema infectiosum, a clinical form most commonly seen in children and adolescents, although it may occur at any age in pregnant women, causing serious or even fatal complications to the fetus. Damage in the erythroid progenitor cells caused by B19V can result in severe anemia, particularly in immunocompromised patients. In addition, B19V infection has been associated with many clinical symptoms, such as neurological and myocardial infections, among others.
1-3 B19V infection is often associated with fever and rash, and many times can be mistakenly reported as measles, rubella or other very common exanthema infections. 4 Based on the phylogenetic analysis of the B19V, it was proposed into three distinct genotypes: 1; 2; and 3 groups. To determine which genotypes of B19V are present in São Paulo city, clinical samples were analyzed, and carried out the genetic characterization of the circulating strains causing exanthematic diseases. That are important tools for regional and global control of viral outbreak.
Method
This study was conducted between 2009 and 2012 at Adolfo Lutz Institute, São Paulo, Brazil, with surveillance specimens collected from 462 patients with suspected B19V. The ages of the patients ranged from 1 month to 55 years of age. Blood samples were collected from individuals with erythema infectiosum, and B19-associated conditions such as encephalitis, hydrops fetalis, severe and chronic anemia, hematological malignancies, and aplastic anemia. Samples were tested using the B19V immunoassay kit and specific immunoglobulin M and G for identification of the VP2 protein (Biotrin International Ltd., Dublin, Ireland). The same samples were processed by real time qPCR (quantitative polymerase chain reaction) and probes were designed to sequence the fragment region of the NS1-VP1 gene, encoding for the B19V non-structural protein (position 1399 to 1659), as previously described by Takano & Yamada, 6 using QIAamp® DNA Blood Mini Kit (Qiagen, Hilden, Germany). The samples were sequenced by nested-PCR using primers described by Servants. 5 The amplified products were purified with PureLink PCR Purification Kit (Invitrogen/Life Technologies, Carlsbad, CA) and sequenced using the ABI Prism Big Dye Terminator v3.1 Cycle Sequencing Kits (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. The sequences obtained were analyzed by CLUSTAL X and BioEdit version 7.0 phylogenetic analysis applications. The sequence generated from the erythrovirus HPV B19 sample was submitted to Blast searches in the GenBank accession numbers, sample from, locations, isolation years, and genotype of the sequences utilized as presented in Table 1 . Alignment was used with prototype sequences of genotype 1: strain Pvbua (Acc.Number M13178), genotype 2: prototype strain Lali (Acc. Number AY044266), and genotype 3: prototype strain V9 (Acc. Number AY647977) by the Clustal X program (http://www-igbmc.u-strasbg.fr/BioInfo/ClustalX/) and analyzed by the Megalign, DNAstar, Inc. software.
results
In order to detect the presence of B19V, an immunoassay of the 462 suspected cases of exanthematic infections was done: 164 (36%) serum samples were positive for B19V IgM and 298 (64%) were positive for B19V IgG. Of the 498 samples analyzed by qPCR, 148 (32%) were found to be positive for B19V protein expression. The infection was equally distributed between male and female patients under the age of 20.
Among the positive samples, 38 with erythema infection and B19-associated were sequenced. The results of the immunoassay (IgG and IgM antibodies) showed 21 samples were positive for both IgM/IgG antibodies, six were negatives IgM/IgG antibodies, seven were positive for IgG antibodies only, and one was positive for IgM only (Table 1) . Among the three samples collected from the cerebrospinal fluid (CSF), one was positive while the remaining two were negative for both IgM/IgG antibodies. The 15 samples clinically negative for IgM and/or IgG antibodies, but positive for the same according to DNA analysis, were collected from patients within 3-5 days after the onset of symptoms. In total, 38 sequences were obtained (eight from samples collected in 2009, 18 from 2010, eight from 2011, and four from 2012). All 38 sequences belonged to genotype1 of B19V (Figure 1 
discussion
In our study, we observed that 36% of the serum samples were positive for B19V IgM and 64% were positive for B19V IgG. In the article described by Candotti et al., 7 the percentage of positivity for IgG and IgM was similar to our findings. Clinical symptoms of B19 infection in 39.8% of the patients exhibiting B19-specific IgM were found in patients from Rio de Janeiro and the same results were obtained. 8 B19V infection causes a benign disease, and neurological complications have been seen but are not usually investigated in encephalitis. 3 Among the cases where the genotype was analyzed, three cases of encephalitis were observed. This was particularly evident in a young man, from whose B19V from CSF was amplified and showed genotype 1.
The incidence of acute B19V infection in pregnancy is approximately 1-2% during the endemic period. However, during the time of an epidemic, the infection rate may rise to > 10%. 9 The peak incidence of B19V-associated hydrops fetalis is between 17 and 24 weeks of gestation. 10, 11 Testing maternal serum for IgM/IgG antibodies against parvovirus B19, and DNA detection by PCR can confirm maternal infection. Among the total number of samples analyzed in our study, three were diagnosed with hydrops fetalis, and all three were positive for infection by parvovirus B19. The rapid correction of anemia by in uterus transfusion of packed erythrocytes largely prevents fetal death. Among the cases analyzed, the majority were associated with hematological disorders. Patients with hemoglobinopathies can be vulnerable to B19V persistence due to shortened red blood cell survival. 12 These persistent infections have been reported to be associated with chronic anemia, thrombocytopenia and pancytopenia, arthralgia, or arthritis. 13 Our results showed high positivity for B19V infection from IgM/G assay and qPCR, in patients with hematological malignancy (Table1).
Our findings are consistent with the results reported by other groups. Studies have reported high positivity for B19V IgG in hematological malignancy cases, aplastic anemia, and chronic hematological disorders. 14, 15 These results are relevant when clinical symptoms are first observed in conditions with a more prolonged evolution of disease with no specific etiological diagnosis and where the disease may be identified by the presence of IgG. Currently, there are three B19V genotypes with associated subtypes, genotype 1a, 1b, 2, 3a, and 3b. 16 The genotypes show ∼10% nucleotide divergence on the whole genome. 5 The most prevalent B19V genotype in Northern Europe is genotype 1a. Genotype 2 appears to be restricted to people born before 1970, and genotype 3 predominantly occurs in people from West Africa, France and Brazil. 17 Some studies have shown that B19V genetic diversity may depend on the geographical location and the year of isolation in patients. In this study, all isolates belonged to genotype 1. 17 In Brazil, all three genotypes have been identified, although genotype 1 is the most common.
14 Genotype 1 has also been isolated in Vietnam, with a higher frequency of occurrence in children and adults. 18   JX559651  JX559657  JX267252  JX559659  JX267257  JX559658  JX559652  JX559650  JX559654  JX559662  JX559655  JX559663  JX465351  JX267259  JX267260  JX559673  JX267261  JX559648  JX559668  JX267253  JX267256  JX559665  JX559653  JX559661  JX267255  JX267258  JX559660  JX559656  JX559671  JX559664  JX559666  JX559649 In addition, genotype 1 is predominant in the Midwest, South and Southeast regions of Brazil. 19, 20 This work shows the presence of B19V genotype 1. Continuous monitoring is necessary to detect all known genotypes, and the emergence of new genotypes related to infection as the cause of virus spread.
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resuMo Genótipo 1 do parvovírus humano em casos clínicos Introdução: Estratégias de vigilância para o parvovírus humano B19 e caracterização genética são ferramentas importantes para o controle regional e global do surto viral. Em São Paulo, Brasil, foi realizado um estudo de parvovírus B19, monitorando a disseminação desse vírus, que é um agente infeccioso e poderia ser erroneamente relatado como uma erupção cutânea e outros tipos de infecções. Método: As amostras de soro foram submetidas ao ensaio imunoenzimático, PCR quantitativo em tempo real e sequenciamento. Resultados: Dos 462 pacientes com casos suspeitos de infecções exantemáticas, os resultados das 164 amostras de soro foram positivos para parvovírus B19 imunoglobulina M. Entre eles, 38 pacientes com eritema infeccioso apresentaram B19 associado com outras infecções, como encefalite, hidropisia fetal, anemia crônica, doenças hematológicas malignas. Essas amostras foram sequenciadas e identificadas como genótipo 1. Conclusão: Os pacientes foram infectados com parvoví-rus B19 e apresentaram genótipo 1. Monitoração contínua é necessária para detectar todos os genótipos conhecidos e o surgimento de novos genótipos para o controle de casos em saúde pública.
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